Skip to main content


for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.

Official Title

A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation


End Stage Renal Disease (ESRD) Chronic Kidney Disease (CKD) Hemodialysis Renal Replacement Therapy Renal Transplantation kidney failure dialysis renal failure transplantation Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic Prednisone Methylprednisolone Everolimus Sirolimus Mycophenolic Acid Tacrolimus Cyclosporins Cyclosporine Thymoglobulin Basiliximab Calcineurin Inhibitors


You can join if…

Open to people ages 18 years and up

  1. Written informed consent obtained.
  2. Subject randomized within 24 hr of completion of transplant surgery.
  3. Recipient of a kidney with a cold ischemia time < 30 hours.
  4. Recipient of a primary (or secondary, if first graft is not lost due to immunological reasons) renal transplant from a deceased heart beating, living unrelated, living related non-human leukocyte antigen identical or an expanded criteria donor.

You CAN'T join if...

  1. Subject unable to tolerate oral medication at time of randomization.
  2. Use of other investigational drugs at the time of enrollment.
  3. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
  4. Multi-organ transplant recipient.
  5. Recipient of ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC)crossmatch positive transplant.
  6. Subject at high immunological risk for rejection as determined by local practice for assessment of anti-donor reactivity e.g. high PRA, presence of pre-existing DSA.
  7. Subject who is HIV-positive.
  8. HBsAg and/or a HCV positive subject with evidence of elevated LFTs (ALT/AST levels ≥2.5 times ULN). Viral serology results obtained within 6 months prior to randomization are acceptable.
  9. Recipient of a kidney from a donor who tests positive for human immunodeficiency virus(HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV).
  10. . Subject with a BMI greater than 35.
  11. . Subject with severe systemic infections, current or within the two weeks prior to randomization.
  12. . Subject requiring systemic anticoagulation.
  13. . History of malignancy of any organ system.
  14. . Subject with severe restrictive or obstructive pulmonary disorders.
  15. . Subject with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled.
  16. . Subject with white blood cell (WBC) count ≤ 2,000 /mm3 or with platelet count ≤ 50,000/mm3.
  17. . Pregnant or nursing (lactating) women.
  18. . Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.


  • Novartis Investigative Site
    San Francisco, California, 94143-0116, United States
  • Novartis Investigative Site
    San Francisco, California, 94115, United States
  • Novartis Investigative Site
    Sacramento, California, 95817-1460, United States
  • Novartis Investigative Site
    Los Angeles, California, 90048, United States
  • Novartis Investigative Site
    Los Angeles, California, 90033, United States
  • Novartis Investigative Site
    Loma Linda, California, 92354, United States


in progress, not accepting new patients
Start Date
Completion Date
Novartis Pharmaceuticals
Phase 4
Lead Scientist
Flavio Vincenti
Study Type
Last Updated
December 1, 2017